Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84,213,667
-
Total 13F shares
-
6,677,932
-
Share change
-
+522,934
-
Total reported value
-
$79,300,000
-
Price per share
-
$11.87
-
Number of holders
-
10
-
Value change
-
+$6,207,670
-
Number of buys
-
3
-
Number of sells
-
2
Institutional Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q4 2017
As of 31 Dec 2017,
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,677,932 shares.
The largest 10 holders included
Vivo Capital, LLC, ORBIMED ADVISORS LLC, NEA Management Company, LLC, venBio Partners L.P., Novo Holdings A/S, Foresite Capital Management III, LLC, Tekla Capital Management LLC, PERCEPTIVE ADVISORS LLC, Polar Capital LLP, and DEUTSCHE BANK AG\.
This page lists
10
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.